
BACKGROUND:Pulmonary hypertension (PH) is a rare but progressive disorder characterized by elevated pressure in the pulmonary arteries. Early diagnosis is essential for effective treatment; however, its nonspecific symptoms often lead to delayed diagnosis. METHODS:In this retrospective cross-sectional study, a total of 648 patients who underwent myocardial perfusion scintigraphy (MPS) were analyzed. The patients were divided into two groups: those suspected of having PH and a control group without such suspicion. Ratios of right ventricular uptake to septal and lateral wall uptake on MPS were compared with pulmonary artery pressures (PAP) measured by transthoracic echocardiography. Correlation analyses focused particularly on changes following exercise. RESULTS:Among patients suspected of having PH, significant positive correlations were observed between right ventricular uptake ratios and PAPs. The p-values for rest right/septum, rest right/lateral, stress right/septum, and stress right/lateral were 0.001, 0.002, 0.001, and 0.001, respectively. This relationship was more pronounced after exercise. In contrast no significant correlation was detected in the control group. These findings indicate that increased right ventricular activity on MPS may reflect early hemodynamic changes associated with PH. CONCLUSIONS:MPS may be considered a non-invasive adjunctive modality that can provide supportive information for the early diagnosis of PH. Nevertheless, due to the retrospective design and absence of invasive confirmation, further prospective studies with larger cohorts are warranted.
BACKGROUND:This review aims to summarize and critically evaluate published clinical trials investigating the role of [18F]FDG PET in bladder cancer (BC) management, and to provide an overview of ongoing trials in this field. METHODS:A literature search was conducted in PubMed up to 31 August 2025 and on ClinicalTrials.gov to identify clinical trials assessing the role of [18F]FDG PET/CT in patients with BC. The search strategy used the terms "FDG PET," "bladder cancer," "PET/CT," "clinical trials," and "PET/MRI." Review articles, editorials, letters, comments, and case reports were excluded. Two investigators independently screened the literature, and additional trial information was retrieved from ClinicalTrials.gov. RESULTS:Five eligible full-text publications and eight registered clinical trials were identified. Among the publications, two reported study protocols, two were pilot studies, and one was an ancillary analysis from a larger trial. In addition, eight ongoing clinical trials were retrieved from ClinicalTrials.gov. Available data suggest that [18F]FDG PET/MRI may be more suitable than PET/CT for evaluating primary bladder lesions, while PET/CT is particularly effective in detecting distant metastases. Several ongoing studies are also investigating delayed acquisition protocols to improve detection of nodal metastases. CONCLUSIONS:[18F]FDG PET/CT and PET/MRI show promise for enhancing local and distant staging in muscle-invasive bladder cancer, although their role in nodal evaluation remains uncertain. Current evidence is limited by heterogeneous study designs, small patient cohorts, and the lack of standardized imaging protocols.
BACKGROUND:Large vessel vasculitis (LVV), encompassing giant cell arteritis (GCA), Takayasu arteritis (TAK) and polymyalgia rheumatica (PMR), is a significant cause of morbidity due to its inflammatory effects on large arteries. Accurate diagnosis is critical but challenging with conventional methods like biopsy or CT/MRI. This umbrella review evaluates the diagnostic performance of [18F]FDG PET/CT, a non-invasive imaging tool for assessing inflammation, in LVV management. METHODS:A comprehensive search was conducted in PubMed/MEDLINE, Embase, Cochrane Library, Scopus, and Web of Science for systematic reviews and meta-analyses published up to February 2025, addressing the research question: "What is the role of [18F]FDG PET/CT in large vessel vasculitis?". Data extraction and quality assessment were performed independently by two reviewers using the Oxford Center for Evidence-Based Medicine criteria. RESULTS:Thirteen systematic reviews met the inclusion criteria, demonstrating high sensitivity (75.9-90%) and specificity (71-98%) of [18F]FDG PET/CT in detecting active LVV, particularly in GCA and TAK. It outperformed CT/MRI in identifying extracranial inflammation and showed promise in treatment monitoring. CONCLUSIONS:[18F]FDG PET/CT is a valuable tool for LVV diagnosis, offering high accuracy and clinical utility. However, emerging technologies such as LAFOV scanners and novel radiotracers, along with advancements in MRI techniques for intracranial assessment, define the new frontiers of diagnostic precision. Its integration into practice may enhance diagnostic precision and treatment strategies, though standardized protocols are needed.